Avelumab and Merkel Cell Carcinoma: Examining the Evidence on Causation and Risk

General Health Communication and Avelumab

General health and science communication has long served as a foundation for public understanding of medical treatments and their associated risks. In this tradition, discussions of therapeutic agents like avelumab—a monoclonal antibody used in oncology—have typically focused on clinical efficacy, patient outcomes, and broad safety profiles. The legacy approach emphasizes balanced, evidence-informed narratives that help patients and providers navigate complex treatment landscapes without overstating or understating potential harms. Transitioning from this general health context to a more focused occupational exposure concern requires a shift in perspective. While clinical settings prioritize patient-centered risk-benefit analyses, occupational health frameworks examine how workers—such as pharmaceutical manufacturing staff, laboratory personnel, or healthcare workers handling the drug—may encounter avelumab outside the therapeutic context. This pivot does not imply causation between occupational exposure and specific diseases, but rather acknowledges that workplace environments can introduce unique exposure pathways. The same scientific rigor applied to patient safety must now be directed toward understanding whether and how non-patient contact with avelumab might influence health outcomes, including potential links to Merkel cell carcinoma. This transition respects the legacy of general health communication while narrowing the lens to occupational settings, where exposure parameters, durations, and routes differ markedly from clinical use.

From General Safety to Occupational Exposure: A Bridge

Building on the foundation of general health communication, it is essential to bridge the gap between patient-focused safety data and occupational health considerations. Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This makes avelumab the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). While these data underscore the drug's therapeutic role, they also provide a baseline for understanding potential risks in non-patient populations. The transition from clinical to occupational contexts requires careful consideration of exposure routes, durations, and biological plausibility, which will be explored in subsequent sections.

Merkel Cell Carcinoma: Etiology and Risk Factors

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the virus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence of MCC is increasing, and it is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). This lack of response or development of immune-related adverse events can be due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three different sites in Germany, clinical and molecular data of patients with metastatic MCC who were refractory to avelumab and later treated with combined ipilimumab and nivolumab were collected and evaluated (https://pubmed.ncbi.nlm.nih.gov/33439294/). Among five patients enrolled, three out of five responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further confirmed that despite the advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Avelumab as Treatment, Not Cause: Evidence Review

From a causation perspective, avelumab is not a cause of Merkel cell carcinoma but rather a treatment for it. The evidence indicates that avelumab is used to treat metastatic MCC, and its approval was based on demonstrated efficacy in clinical trials (https://pubmed.ncbi.nlm.nih.gov/29799096/). The risk narrative for patients involves understanding that avelumab, as an immune checkpoint inhibitor, can lead to immune-related adverse events, and that approximately half of patients may not respond to therapy or may experience progression (https://pubmed.ncbi.nlm.nih.gov/35877101/). The timeline between exposure to avelumab and health outcomes is typically measured in weeks to months during treatment, with response assessments conducted per RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). For patients who are refractory, alternative treatments such as combined ipilimumab and nivolumab may be considered, as evidenced by response rates in small studies (https://pubmed.ncbi.nlm.nih.gov/33439294/). In summary, avelumab is an established treatment for metastatic Merkel cell carcinoma, not a causative agent. The evidence supports its role in improving outcomes for some patients, while also highlighting the need for alternative strategies for those who do not respond. Safety communication should focus on the balance of benefits and risks, including the potential for immune-related adverse events and the possibility of non-response.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified medical contexts for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, avelumab is not a cause of Merkel cell carcinoma. It is a treatment for metastatic Merkel cell carcinoma, approved based on clinical trials showing efficacy in shrinking tumors. The known causes of MCC are ultraviolet light exposure and Merkel cell polyomavirus.

What is the risk of developing Merkel cell carcinoma from occupational exposure to avelumab?

There is no evidence that occupational exposure to avelumab increases the risk of Merkel cell carcinoma. Avelumab is a monoclonal antibody that targets PD-L1 and is used therapeutically. Studies have not linked non-patient exposure to MCC development.

What does the evidence say about avelumab and Merkel cell carcinoma risk?

The evidence consistently shows that avelumab is an effective treatment for Merkel cell carcinoma, not a risk factor. Clinical trials demonstrate response rates in about one-third of patients, and no studies suggest a causal role in MCC development.

Does submitting information create an medical context-client relationship?

No. Submission requests an initial records screening only and does not create an medical context-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.